SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.

Robert J. Jones, Simon J. Crabb, Johann S. de Bono et al.|Journal of Clinical Oncology|2021

Cited by 3